⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148684 | 0.67 | — | — | |
| SCHEMBL17111366 | 0.64 | — | — | |
| SCHEMBL1979459 | 0.61 | — | — | |
| SCHEMBL184646 | 0.58 | — | — | |
| SCHEMBL8888694 | 0.58 | — | — | |
| SCHEMBL58696 | 0.51 | — | — | |
| SCHEMBL384339 | 0.51 | — | — | |
| SCHEMBL3215285 | 0.48 | — | — | |
| SCHEMBL6369 | 0.48 | — | — | |
| SCHEMBL9182568 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238634-A1 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same | MERCHANT FACTORS CORP | 2015-08-27 | — | — | US | claimed |
| US-20140155348-A1 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same | ZAFGEN, INC. (US) | 2014-06-05 | — | — | US | claimed |
| US-20130029936-A1 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same | KIM JAE HYUN (KR) | 2013-01-31 | — | — | US | claimed |
| US-20110034550-A1 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same | KIM JAE HYUN | 2011-02-10 | — | — | US | claimed |
| US-20080085929-A1 | Of derivatives such as O-(3,4,5-trimethoxycinnamoyl)fumagillol with hydroxypropyl-beta-cyclodextrin or sulfobutylether-7-beta-cyclodextrin; antimetastatic agent; antitumor agent; sustained release dosage forms | KIM JAE HYUN | 2008-04-10 | — | — | US | claimed |
| US-20050037994-A1 | Water soluble; low toxicity; anticancer agents; antitumor agenst | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2005-02-17 | — | — | US | claimed |
| WO-2003082845-A1 | INCLUSION COMPOUNDS OF FUMAGILLOL DERIVATIVE OR ITS SALT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2003-10-09 | — | — | WO | claimed |
| US-6063812-A | ANGIOGENESIS INHIBITORS, ANTIARTHRITIC AGENTS AND ANTICARCINOGENIC AGENTS PLUS SYNTHESIS | CHONG KUN DANG CORPORATION (KR) | 2000-05-16 | — | — | US | claimed |
| WO-1999029640-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR | EISAI CO., LTD. (JP) | 1999-06-17 | — | — | WO | claimed |
| US-20200054766-A1 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2020-02-20 | — | — | US | disclosed |
| US-20180271999-A1 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-09-27 | — | — | US | disclosed |
| US-20180016249-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170209596-A1 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same | ZAFGEN INC (US) | 2017-07-27 | — | — | US | disclosed |
| US-9701651-B2 | Methods of treating an overweight or obese subject | ZAFGEN, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| WO-2010065877-A2 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN CORPORATION (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7718695-B2 | Of derivatives such as O-(3,4,5-trimethoxycinnamoyl)fumagillol with hydroxypropyl-beta-cyclodextrin or sulfobutylether-7-beta-cyclodextrin; antimetastatic agent; antitumor agent; sustained release dosage forms | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2010-05-18 | — | — | US | disclosed |
| US-20080085929-A1 | Of derivatives such as O-(3,4,5-trimethoxycinnamoyl)fumagillol with hydroxypropyl-beta-cyclodextrin or sulfobutylether-7-beta-cyclodextrin; antimetastatic agent; antitumor agent; sustained release dosage forms | KIM JAE HYUN | 2008-04-10 | — | — | US | disclosed |
| US-20050037994-A1 | Water soluble; low toxicity; anticancer agents; antitumor agenst | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2005-02-17 | — | — | US | disclosed |
| WO-2003082845-A1 | INCLUSION COMPOUNDS OF FUMAGILLOL DERIVATIVE OR ITS SALT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2003-10-09 | — | — | WO | disclosed |
| WO-1999029640-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR | EISAI CO., LTD. (JP) | 1999-06-17 | — | — | WO | disclosed |